Theriva Biologics, Inc. Grants Receivable, Current
Theriva Biologics, Inc. (TOVX) had Grants Receivable, Current of $1.68 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Nontrade Receivables › Nontrade Receivables, Current
us-gaap:GrantsReceivableCurrent · last filed 2026-08-11
- 2026-06-30: Grants Receivable, Current $1.68M.
- 2026-03-31: Grants Receivable, Current $1.70M.
- 2025-12-31: Grants Receivable, Current $3.35M.
- 2025-09-30: Grants Receivable, Current $1.72M.
| Period end | Grants Receivable, Current |
|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.35M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $1.72M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.72M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.59M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.23M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.83M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.76M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.77M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.81M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.40M 10-Q · filed 2023-11-13 |
| 2017-09-30 | $130.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | $315.00K 10-Q · filed 2017-08-03 |
| 2016-12-31 | $185.00K 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |